Mirum Pharmaceuticals Inc (MIRM)vsModerna Inc (MRNA)
MIRM
Mirum Pharmaceuticals Inc
$91.39
-0.66%
HEALTHCARE · Cap: $5.97B
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 260% more annual revenue ($2.23B vs $618.07M). MIRM leads profitability with a -139.2% profit margin vs -141.4%. MIRM earns a higher WallStSmart Score of 30/100 (F).
MIRM
Avoid30
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.5%
Fair Value
$186.51
Current Price
$91.39
$95.12 discount
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37.9% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of -329.4% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth, Debt/Equity. Revenue growth of 37.9% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MIRM profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MIRM is growing revenue faster at 37.9% — sustainability is the question.
MIRM generates stronger free cash flow (-274M), providing more financial flexibility.
Bottom Line
MIRM scores higher overall (30/100 vs 21/100) and 37.9% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?